Swanson, Todd A.
Mayo Clinic
The University of Texas MD Anderson Cancer Center
Citations 2
A phase II clinical trial of frameless, fractionated stereotactic radiation therapy for brain metastases
Schlembach, Pamela J., Bowers, John, McAleer, Mary Frances , Brown, Paul D. , Gopal, Ramesh, Wiederhold, Lee, Swanson, Todd A. , Li, Jing , Ferguson, Sherise D. , Philip, Nancy V, DeGracia, Lilybeth, Bloom, Elizabeth S., Chun, Stephen G , Garg, Amit Kumar , Hernández, Mike , Shah, Shalin J. , Philip, Nancy V., Chun, Stephen G.
JNCI Cancer Spectrum | November 9, 2023 | Volume: 7 | Issue: 6 | Pages: No page available
Abstract Stereotactic radiation therapy yields high rates of local control for brain metastases, but patients in rural or suburban areas face geographic and socioeconomic barriers to its access. We conducted a phase II clinical trial of frameless, fractionated stereotactic radiation therapy for brain metastases in an integrated academic satellite network for patients 18 years of age or older with 4 or fewer brain metastases. Dose was based on gross tumor volume: less than 3.0 cm, 27 Gy in 3 fractions and 3.0 to 3.9 cm, 30 Gy in 5 fractions. Median follow-up was 10 months for 73 evaluable patients, with a median age of 68 years. Median intracranial progression-free survival was 7.1 months (95% confidence interval = 5.3 to not reached), and median survival was 7.2 months (95% confidence interval = 5.4 to not reached); there were no serious adverse events. Outcomes of this trial compare favorably with contemporary trials, and this treatment strategy provides opportunities to expand stereotactic radiation therapy access to underserved populations.
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma
Hasanov, Elshad , Yeboa, D.N. , Tucker, Mathew D., Swanson, Todd A. , Ene, Chibawanye , Hasanov, Merve , Derks, Sophie H. A. E. , Smits, Marion , Dudani, Shaan , Heng, Daniel Y.C., Bex, Axel , Hanalıoğlu, Şahin , Weinberg, Jeffrey S. , Hirsch, Laure , Carlo, Maria I. , Aizer, Ayal A. , Brown, Paul D. , Bilen, Mehmet Asım , Chang, Eric L. , Jaboin, Jerry J. , Choueiri, Toni K. , Halasz, Lia M. , Patel, Toral , Soltys, Scott G. , Elder, J. Bradley , Başkaya, Mustafa K. , Timmerman, Robert , Kim, Michelle Miran, Mut, Melike , Beal, Kathryn , Lang, Frederick F. , Giles, Rachel , Patel, Toral , Brown, Paul David, Choueiri, Toni K , Smits, Marion , Hanalioglu, Sahin , Patel, Toral R , Beckham, Thomas Hendrix , Rini, Brian I. , Brastianos, Priscilla K. , Brugarolas, James , Atkins, Michael B. , McGregor, Bradley A. , McDermott, David F. , Yu, James B. , Kim, Michelle H. , Markert, James M. , Tannir, Nizar , Samandouras, George , Jonasch, Eric W.
CA: A Cancer Journal for Clinicians | June 16, 2022 | Volume: 72 | Issue: 5 | Pages: 454-489
Abstract Brain metastases are a challenging manifestation of renal cell carcinoma. We have a limited understanding of brain metastasis tumor and immune biology, drivers of resistance to systemic treatment, and their overall poor prognosis. Current data support a multimodal treatment strategy with radiation treatment and/or surgery. Nonetheless, the optimal approach for the management of brain metastases from renal cell carcinoma remains unclear. To improve patient care, the authors sought to standardize practical management strategies. They performed an unstructured literature review and elaborated on the current management strategies through an international group of experts from different disciplines assembled via the network of the International Kidney Cancer Coalition. Experts from different disciplines were administered a survey to answer questions related to current challenges and unmet patient needs. On the basis of the integrated approach of literature review and survey study results, the authors built algorithms for the management of single and multiple brain metastases in patients with renal cell carcinoma. The literature review, consensus statements, and algorithms presented in this report can serve as a framework guiding treatment decisions for patients. CA Cancer J Clin. 2022;72:454‐489.